IP Library Granted Patent US 9,453,037
Granted Patent B2
US 9,453,037 · App. 14/727,498 · Granted Sep 27, 2016

Methylphenidate-prodrugs, processes of making and using the same

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,453,037
App. No.
14/727,498
Granted
Sep 27, 2016
Kind
B2
Abstract

The present technology is directed to prodrugs and compositions for the treatment of various diseases and/or disorders comprising methylphenidate, or methylphenidate derivatives, conjugated to at least one alcohol, amine, oxoacid, thiol, or derivatives thereof. In some embodiments, the conjugates further include at least one linker. The present technology also relates to the synthesis of methylphenidate, or methylphenidate derivatives, conjugated to at least one alcohol, amine, oxoacid, thiol, or derivatives thereof or combinations thereof.

Claims (8)

1. A composition comprising: at least one conjugate of methylphenidate, wherein the conjugate of methylphenidate has the following structure:

wherein G 2 is independently selected from the group consisting of standard amino acids, nonstandard amino acids and synthetic amino acids, wherein the amino acid is attached to the rest of the molecule by an amide linkage.

2. The composition of claim 1 , wherein G 2 is selected from the group consisting of Phe, His, Ile, and Pro.

3. The composition of claim 1 , wherein the conjugate of methylphenidate has the following structure:

4. The composition of claim 1 , wherein the conjugate of methylphenidate is Phe-(6-aminohexanoyl)-CH 2 OCO-MPH.

5. A composition comprising: at least one conjugate of methylphenidate, wherein the conjugate of methylphenidate has the following structure:

wherein G 2 and G 3 are independently selected from the group consisting of standard amino acids, nonstandard amino acids and synthetic amino acids, wherein the amino acid is attached to the rest of the molecule by an amide linkage.

6. The composition of claim 5 , wherein G 2 and G 3 are independently selected from the group consisting of Phe and Pro.

Assignments (7)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 26, 2026
From: ZEVRA THERAPEUTICS, INC.
To: COMMAVE THERAPEUTICS SA
Reel/Frame 074194/0909 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 25, 2026
From: ZEVRA THERAPEUTICS, INC.
To: COMMAVE THERAPEUTICS SA
Reel/Frame 074186/0531 →
RELEASE OF SECURITY INTEREST Recorded Mar 13, 2026
From: ALTER DOMUS (US) LLC
To: ZEVRA THERAPEUTICS, INC.
Reel/Frame 075080/0907 →
SECURITY INTEREST Recorded Apr 8, 2024
From: ZEVRA THERAPEUTICS, INC.
To: ALTER DOMUS (US) LLC
Reel/Frame 067040/0637 →
CHANGE OF NAME Recorded Feb 26, 2024
From: KEMPHARM, INC.
To: ZEVRA THERAPEUTICS, INC.
Reel/Frame 066679/0668 →
CORRECTIVE ASSIGNMENT TO CORRECT THE ASSIGNEE'S ADDRESS PREVIOUSLY RECORDED AT REEL: 037531 FRAME: 0375. ASSIGNOR(S) HEREBY CONFIRMS THE ASSIGNMENT. Recorded Sep 5, 2018
From: GUENTHER, SVEN; CHI, GUOCHEN; BERA, BINDU; MICKLE, TRAVIS; BERA, SANJIB
To: KEMPHARM, INC.
Reel/Frame 047021/0469 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jan 20, 2016
From: GUENTHER, SVEN; CHI, GUOCHEN; BERA, BINDU; BERA, SANJIB; MICKLE, TRAVIS
To: KEMPHARM, INC.
Reel/Frame 037531/0211 →